Main content area

Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

Attwa, Mohamed W., Kadi, Adnan A., Darwish, Hany W., Abdelhameed, Ali S.
RSC advances 2018 v.8 no.70 pp. 40387-40394
enzyme inhibitors, epidermal growth factor receptors, half life, humans, liquid chromatography, lung neoplasms, metastasis, patients, tandem mass spectrometry, South Korea
Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). It was developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd for the cure of non-small cell lung cancer (NSCLC). In May 2016, OTB was approved in South Korea for the treatment of patients suffering from metastatic or locally advanced EGFR T790M mutation-positive NSCLC. A LC-MS/MS methodology was validated for OTB quantification in human plasma. An extended application for this validated LC-MS/MS is OTB metabolic stability evaluation. Chromatographic separation of OTB and ponatinib (PNT, IS) was attained using a reversed phase with isocratic elution. The linearity of the developed LC-MS/MS method ranged from 5.00 to 500.00 ng mL⁻¹ with r² ≥ 0.9999 in human plasma. LOD and LOQ were 1.12 and 3.39 ng mL⁻¹, respectively. The intra-day and inter-day precision and accuracy were 1.17 to 2.75% and 97.86 to 101.48%, respectively. The intrinsic clearance (CLᵢₙₜ) was 2.71 mL min⁻¹ kg⁻¹ and the in vitro half-life (t₁/₂) was 48.80 min. A review of the literature revealed that there are no previous articles about the quantification of OTB in human plasma using LC-MS/MS or its metabolic stability assessment.